Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of “Moderate Buy” by Analysts

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has been given an average rating of “Moderate Buy” by the ten brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $41.00.

Several analysts recently issued reports on the company. HC Wainwright lifted their target price on Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Oppenheimer increased their price objective on shares of Olema Pharmaceuticals from $45.00 to $48.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. Piper Sandler started coverage on shares of Olema Pharmaceuticals in a report on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Thursday, January 22nd. Finally, UBS Group started coverage on shares of Olema Pharmaceuticals in a report on Wednesday, January 7th. They issued a “buy” rating and a $45.00 price target on the stock.

Insider Activity

In other news, insider Naseem Zojwalla sold 100,000 shares of Olema Pharmaceuticals stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $28.04, for a total value of $2,804,000.00. Following the sale, the insider directly owned 53,997 shares of the company’s stock, valued at approximately $1,514,075.88. The trade was a 64.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider David C. Myles sold 51,000 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $30.46, for a total value of $1,553,460.00. Following the transaction, the insider directly owned 551,881 shares of the company’s stock, valued at approximately $16,810,295.26. The trade was a 8.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 765,501 shares of company stock valued at $22,052,432. 16.36% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC lifted its position in Olema Pharmaceuticals by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after purchasing an additional 477 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Olema Pharmaceuticals by 8.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,018 shares of the company’s stock worth $325,000 after buying an additional 987 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Olema Pharmaceuticals by 44.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after buying an additional 1,169 shares in the last quarter. Torren Management LLC bought a new position in shares of Olema Pharmaceuticals in the 4th quarter valued at about $44,000. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of Olema Pharmaceuticals by 55.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock valued at $26,000 after acquiring an additional 2,168 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Olema Pharmaceuticals Stock Down 5.0%

OLMA opened at $25.01 on Friday. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -13.37 and a beta of 1.89. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. The firm’s fifty day moving average is $27.49 and its 200 day moving average is $15.34. Olema Pharmaceuticals has a fifty-two week low of $2.86 and a fifty-two week high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). On average, sell-side analysts forecast that Olema Pharmaceuticals will post -2.33 earnings per share for the current fiscal year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.